Laurence J N Cooper

This inventor holds 16 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 1 EPO patent. Top assignees: The University of Texas System, Sangamo Therapeutics, Inc., Sangamo Biosciences, Inc.. Active years: 2015-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Laurence J N Cooper. Retrieved from https://idiyas.com/inventor/laurence-j-n-cooper

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 1)

% Patents Active = 93.8

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 2.8

ph-index = 6

Forward Citations = 167(Granted Patents)

Location History:

Austin, TX (US) (2015 - 2020)
Houston, TX (US) (2017 - 2024)

Company Filing History:

16 out of 5,638

The University of Texas System

patents

2 out of 154

Sangamo Therapeutics, Inc.

patents

1 out of 160

Sangamo Biosciences, Inc.

patents

where one patent can have more than one assignee

Years Active: 2015-2024

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12116604 - Transposase polypeptides and uses thereof (2024-10-15),

2. 12065490 - Chimeric antigen receptors and methods of making (2024-08-20),

3. 11786582 - Human application of engineered chimeric antigen receptor (CAR) T-cells (2023-10-17),

4. 11548945 - T-cell receptor (TCR)-binding antibodies and uses thereof (2023-01-10),

5. 11492604 - Transposase polypeptides and uses thereof (2022-11-08),

6. 10883094 - Transposase polypeptides and uses thereof (2021-01-05),

7. 10858416 - Methods and compositions for modification of a HLA locus (2020-12-08),

8. 10808230 - Selection methods for genetically-modified T cells (2020-10-20),

9. 10633445 - T-cell receptor (TCR)-binding antibodies and uses thereof (2020-04-28),

10. 10570382 - Transposase polypeptides and uses thereof (2020-02-25),

11. 10570186 - Chimeric antigen receptors (CAR) to selectively target protein complexes (2020-02-25),

12. 10125193 - Chimeric antigen receptors and methods of making (2018-11-13),

13. 10072062 - Methods and compositions for modification of a HLA locus (2018-09-11),

14. 9907820 - Polyclonal gamma delta T cells for immunotherapy (2018-03-06),

15. 9701758 - Anti-CD19 scFv (FMC63) polypeptide (2017-07-11),

Title: The Innovative Journey of Laurence J N Cooper

Introduction: Laurence J N Cooper is a renowned inventor based in Houston, Texas, known for his groundbreaking contributions to the field of biotechnology and healthcare.

Latest Patents: Laurence J N Cooper holds several patents related to novel cancer therapies and immunotherapy techniques, showcasing his commitment to advancing medical treatments.

Career Highlights: With a background in bioengineering and immunology, Laurence J N Cooper has had a distinguished career working in both academic and industry settings, where he has spearheaded numerous research projects leading to significant advancements in the medical field.

Collaborations: Throughout his career, Laurence J N Cooper has collaborated with leading researchers, healthcare professionals, and pharmaceutical companies to further develop and implement his innovative ideas, resulting in the successful translation of his inventions into real-world applications.

Conclusion: Laurence J N Cooper's dedication to innovation and his relentless pursuit of improving healthcare through his inventions have solidified his reputation as a pioneering inventor in the field of biotechnology.

Profile summary based on public USPTO records.